These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1577 related items for PubMed ID: 15736186

  • 1. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
    Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O.
    Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
    [Abstract] [Full Text] [Related]

  • 2. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [Abstract] [Full Text] [Related]

  • 3. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies.
    Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2002 Sep; 20(3):219-25. PubMed ID: 12230441
    [Abstract] [Full Text] [Related]

  • 4. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [Abstract] [Full Text] [Related]

  • 5. Prospective validation of first-trimester combined screening for trisomy 21.
    Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2009 Jul; 34(1):14-8. PubMed ID: 19526452
    [Abstract] [Full Text] [Related]

  • 6. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [Abstract] [Full Text] [Related]

  • 7. First-trimester screening for chromosomal abnormalities.
    Nicolaides KH.
    Semin Perinatol; 2005 Aug; 29(4):190-4. PubMed ID: 16104667
    [Abstract] [Full Text] [Related]

  • 8. First trimester predictors of adverse pregnancy outcomes.
    Brameld KJ, Dickinson JE, O'Leary P, Bower C, Goldblatt J, Hewitt B, Murch A, Stock R.
    Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
    [Abstract] [Full Text] [Related]

  • 9. Comparison of serum markers in first-trimester down syndrome screening.
    Canick JA, Lambert-Messerlian GM, Palomaki GE, Neveux LM, Malone FD, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Saade GR, Berkowitz RL, Dar P, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME, First and Second Trimester Evaluation of Risk (FASTER) Trial Research Consortium.
    Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
    [Abstract] [Full Text] [Related]

  • 10. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
    Soergel P, Pruggmayer M, Schwerdtfeger R, Muhlhaus K, Scharf A.
    Fetal Diagn Ther; 2006 Nov; 21(3):264-8. PubMed ID: 16601335
    [Abstract] [Full Text] [Related]

  • 11. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
    Spencer K, Cowans NJ, Avgidou K, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2006 Oct; 28(5):637-43. PubMed ID: 16952214
    [Abstract] [Full Text] [Related]

  • 12. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
    Spencer K, Bindra R, Cacho AM, Nicolaides KH.
    Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
    [Abstract] [Full Text] [Related]

  • 13. Comparison of first-trimester contingent screening strategies for Down syndrome.
    Sahota DS, Leung TY, Chan LW, Law LW, Fung TY, Chen M, Lau TK.
    Ultrasound Obstet Gynecol; 2010 Mar; 35(3):286-91. PubMed ID: 20052660
    [Abstract] [Full Text] [Related]

  • 14. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
    Breathnach FM, Malone FD, Lambert-Messerlian G, Cuckle HS, Porter TF, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Klugman S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Tripp T, Bianchi DW, D'Alton ME, First and Second Trimester Evaluation of Risk (FASTER) Research Consortium.
    Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
    [Abstract] [Full Text] [Related]

  • 15. First-trimester screening for trisomy 21 in twin pregnancy: does the addition of biochemistry make an improvement?
    Goncé A, Borrell A, Fortuny A, Casals E, Martínez MA, Mercadé I, Cararach V, Vanrell JA.
    Prenat Diagn; 2005 Dec; 25(12):1156-61. PubMed ID: 16231401
    [Abstract] [Full Text] [Related]

  • 16. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S, Spencer K, Avgidou K, Faiola S, Nicolaides KH.
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [Abstract] [Full Text] [Related]

  • 17. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
    Karadzov-Orlić N, Egić A, Filimonović D, Marinković M, Damnjanović-Pazin B, Milovanović Z, Joksić I, Branković S, Lukić R, Mandić V, Cerović N, Mojović D, Plamenac S, Stanković M, Maglić D, Mikovć Z.
    Srp Arh Celok Lek; 2012 Nov; 140(9-10):606-11. PubMed ID: 23289277
    [Abstract] [Full Text] [Related]

  • 18. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
    Chen X, Chang Y, Cui HY, Ren CC, Yu BY.
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
    [Abstract] [Full Text] [Related]

  • 19. Does vaginal bleeding influence first-trimester markers for Down syndrome?
    Heinig J, Steinhard J, Schmitz R, Nofer JR, Witteler R, Mosel A, Ahrens A, Kiesel L, Klockenbusch W.
    Prenat Diagn; 2007 Apr; 27(4):312-6. PubMed ID: 17286311
    [Abstract] [Full Text] [Related]

  • 20. A new approach to calculating the risk of chromosomal abnormalities with first-trimester screening data.
    Merz E, Thode C, Alkier A, Eiben B, Hackelöer BJ, Hansmann M, Huesgen G, Kozlowski P, Pruggmaier M, Wellek S.
    Ultraschall Med; 2008 Dec; 29(6):639-45. PubMed ID: 19085755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 79.